Published in PLoS One on July 02, 2008
Genetic evidence supporting a critical role of endothelial caveolin-1 during the progression of atherosclerosis. Cell Metab (2009) 1.44
Membrane rafts and caveolae in cardiovascular signaling. Curr Opin Nephrol Hypertens (2009) 1.19
Lipid rafts and caveolae and their role in compartmentation of redox signaling. Antioxid Redox Signal (2009) 1.02
Caveolin-1 deficiency decreases atherosclerosis by hampering leukocyte influx into the arterial wall and generating a regulatory T-cell response. FASEB J (2011) 0.94
10-years experience with the Athero-Express study. Cardiovasc Diagn Ther (2012) 0.93
Alterations in Pulse Pressure Affect Artery Function. Cell Mol Bioeng (2012) 0.84
Caveolae control the anti-inflammatory phenotype of senescent endothelial cells. Aging Cell (2014) 0.79
Myocardin Family Members Drive Formation of Caveolae. PLoS One (2015) 0.79
Regulation of Cell Signaling and Function by Endothelial Caveolins: Implications in Disease. Transl Med (Sunnyvale) (2012) 0.77
Nitric Oxide Induces Cardiac Protection by Preventing Extracellular Matrix Degradation through the Complex Caveolin-3/EMMPRIN in Cardiac Myocytes. PLoS One (2016) 0.77
Contemporary Approaches to Modulating the Nitric Oxide-cGMP Pathway in Cardiovascular Disease. Circ Res (2017) 0.76
Early biventricular molecular responses to an acute myocardial infarction. Int J Med Sci (2011) 0.75
Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med (2005) 28.21
Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med (1991) 18.33
Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet (2004) 12.59
Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST) Lancet (1998) 10.64
Coronary plaque disruption. Circulation (1995) 8.04
Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest (1994) 7.25
Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med (1997) 5.09
In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med (2000) 3.37
Evidence of a chronic systemic cause of instability of atherosclerotic plaques. Lancet (2000) 3.07
Genetic ablation of caveolin-1 confers protection against atherosclerosis. Arterioscler Thromb Vasc Biol (2003) 2.33
Caveolae and caveolins in the cardiovascular system. Circ Res (2004) 2.24
Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell (2003) 2.16
Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol (2003) 2.10
Links between CD147 function, glycosylation, and caveolin-1. Mol Biol Cell (2004) 1.62
In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation (2002) 1.61
Caveolin-1 confers antiinflammatory effects in murine macrophages via the MKK3/p38 MAPK pathway. Am J Respir Cell Mol Biol (2005) 1.51
Toll-like receptor 4 is involved in outward arterial remodeling. Circulation (2003) 1.43
Expansive arterial remodeling: location, location, location. Arterioscler Thromb Vasc Biol (2004) 1.31
Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. Circulation (2006) 1.31
A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity. J Dent Res (1987) 1.31
Caveolin-1 regulates matrix metalloproteinases-1 induction and CD147/EMMPRIN cell surface clustering. J Biol Chem (2004) 1.25
Athero-express: differential atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and patient characteristics. Rationale and design. Eur J Epidemiol (2004) 1.23
Caveolin-1 deficiency stimulates neointima formation during vascular injury. Biochemistry (2004) 1.22
Caveolin-1 and caveolae in atherosclerosis: differential roles in fatty streak formation and neointimal hyperplasia. Curr Opin Lipidol (2004) 1.15
Carotid atherosclerotic plaques in patients with transient ischemic attacks and stroke have unstable characteristics compared with plaques in asymptomatic and amaurosis fugax patients. J Vasc Surg (2005) 1.09
Caveolae and caveolin-1: novel potential targets for the treatment of cardiovascular disease. Curr Pharm Des (2007) 1.09
Intraobserver and interobserver variability and spatial differences in histologic examination of carotid endarterectomy specimens. J Vasc Surg (2007) 1.08
Vascular remodeling and protease inhibition--bench to bedside. Cardiovasc Res (2006) 1.07
Gender-associated differences in plaque phenotype of patients undergoing carotid endarterectomy. J Vasc Surg (2007) 1.05
Decreased caveolin-1 in atheroma: loss of antiproliferative control of vascular smooth muscle cells in atherosclerosis. Cardiovasc Res (2005) 1.02
From vulnerable plaque to vulnerable patient: the search for biomarkers of plaque destabilization. Trends Cardiovasc Med (2007) 0.97
Caveolin-1 inhibits matrix metalloproteinase-2 activity in the heart. J Mol Cell Cardiol (2007) 0.95
Coronary artery disease: arterial remodelling and clinical presentation. Heart (1999) 0.89
Furin and membrane type-1 metalloproteinase mRNA levels and activation of metalloproteinase-2 are associated with arterial remodeling. FEBS Lett (2001) 0.88
Dose-dependent limitation of arterial enlargement by the matrix metalloproteinase inhibitor RS-113,456. J Surg Res (1999) 0.87
Caveolin-1 expression is associated with plaque formation in hypercholesterolemic rabbits. J Histochem Cytochem (2006) 0.87
Caveolin-1, Id3a and two LIM protein genes are upregulated by estrogen in vascular smooth muscle cells. Life Sci (2004) 0.81
Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet (2010) 11.00
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol (2007) 6.15
Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol (2010) 5.79
A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. N Engl J Med (1991) 5.69
Evolving functions of endothelial cells in inflammation. Nat Rev Immunol (2007) 4.94
Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res (2007) 4.72
Nitric oxide synthases: regulation and function. Eur Heart J (2011) 4.71
Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell (2006) 4.55
The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J (2008) 4.49
Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data. Lancet (2010) 4.07
Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res (2010) 4.06
Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. J Clin Invest (2005) 3.95
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol (2012) 3.93
Surgical decompression for space-occupying cerebral infarction (the Hemicraniectomy After Middle Cerebral Artery infarction with Life-threatening Edema Trial [HAMLET]): a multicentre, open, randomised trial. Lancet Neurol (2009) 3.89
Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med (2006) 3.80
Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis. Lancet Neurol (2011) 3.73
Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol (2009) 3.66
Risk of rupture of unruptured intracranial aneurysms in relation to patient and aneurysm characteristics: an updated meta-analysis. Stroke (2007) 3.59
Treatment of brain arteriovenous malformations: a systematic review and meta-analysis. JAMA (2011) 3.40
Treatment and outcomes of acute basilar artery occlusion in the Basilar Artery International Cooperation Study (BASICS): a prospective registry study. Lancet Neurol (2009) 3.36
Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. Lancet (2012) 3.14
Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc Natl Acad Sci U S A (2008) 3.03
Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release. Circ Res (2002) 3.01
Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol (2009) 2.94
National Stroke Association guidelines for the management of transient ischemic attacks. Ann Neurol (2006) 2.82
Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc Natl Acad Sci U S A (2005) 2.81
The Paracetamol (Acetaminophen) In Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial. Lancet Neurol (2009) 2.78
Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes (2006) 2.77
Seventy-five genetic loci influencing the human red blood cell. Nature (2012) 2.77
In vivo cell seeding with anti-CD34 antibodies successfully accelerates endothelialization but stimulates intimal hyperplasia in porcine arteriovenous expanded polytetrafluoroethylene grafts. Circulation (2005) 2.69
Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res (2007) 2.69
A new role for Nogo as a regulator of vascular remodeling. Nat Med (2004) 2.63
Loss of Akt1 leads to severe atherosclerosis and occlusive coronary artery disease. Cell Metab (2007) 2.53
Direct evidence for the role of caveolin-1 and caveolae in mechanotransduction and remodeling of blood vessels. J Clin Invest (2006) 2.47
Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation (2008) 2.42
Risk factors for subarachnoid hemorrhage: an updated systematic review of epidemiological studies. Stroke (2005) 2.41
Long-term outcomes of patients with aneurysmal subarachnoid haemorrhage. Lancet Neurol (2011) 2.38
Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol (2009) 2.37
Asymptomatic carotid artery stenosis and the risk of new vascular events in patients with manifest arterial disease: the SMART study. Stroke (2007) 2.36
MicroRNAs as novel regulators of angiogenesis. Circ Res (2009) 2.33
Growth predictors and prognosis of small abdominal aortic aneurysms. J Vasc Surg (2008) 2.31
Caveolae and caveolins in the cardiovascular system. Circ Res (2004) 2.24
Caveolin regulation of endothelial function. Am J Physiol Lung Cell Mol Physiol (2003) 2.22
Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med (2009) 2.17
Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy. Circulation (2014) 2.16
Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell (2003) 2.16
Endograft collapse after thoracic endovascular aortic repair. J Endovasc Ther (2010) 2.11
Characterizing vulnerable plaque features with intravascular elastography. Circulation (2003) 2.07
Nurses' prediction of volume status after aneurysmal subarachnoid haemorrhage: a prospective cohort study. Crit Care (2008) 2.06
Reexpression of caveolin-1 in endothelium rescues the vascular, cardiac, and pulmonary defects in global caveolin-1 knockout mice. J Exp Med (2007) 2.04
Acute management of aortobronchial and aortoesophageal fistulas using thoracic endovascular aortic repair. J Vasc Surg (2009) 2.02
MicroRNAs are necessary for vascular smooth muscle growth, differentiation, and function. Arterioscler Thromb Vasc Biol (2010) 2.00
Impaired glucose tolerance increases stroke risk in nondiabetic patients with transient ischemic attack or minor ischemic stroke. Stroke (2006) 1.99
TGF-beta1 induces efficient differentiation of human cardiomyocyte progenitor cells into functional cardiomyocytes in vitro. Stem Cell Res (2008) 1.98
Compensatory phosphorylation and protein-protein interactions revealed by loss of function and gain of function mutants of multiple serine phosphorylation sites in endothelial nitric-oxide synthase. J Biol Chem (2003) 1.98
Nitric oxide synthase generates nitric oxide locally to regulate compartmentalized protein S-nitrosylation and protein trafficking. Proc Natl Acad Sci U S A (2006) 1.97
Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res (2008) 1.97
Trigger factors and their attributable risk for rupture of intracranial aneurysms: a case-crossover study. Stroke (2011) 1.96
Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. Stem Cell Res (2013) 1.96
The role of Nogo and the mitochondria-endoplasmic reticulum unit in pulmonary hypertension. Sci Transl Med (2011) 1.95
Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation (2009) 1.94
Src kinase mediates phosphatidylinositol 3-kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation by estrogen. J Biol Chem (2002) 1.91
Regulation of survivin function by Hsp90. Proc Natl Acad Sci U S A (2003) 1.86
Growth rates of intracranial aneurysms: exploring constancy. J Neurosurg (2008) 1.85
Meta-analysis in more than 17,900 cases of ischemic stroke reveals a novel association at 12q24.12. Neurology (2014) 1.85
Dominant-negative Hsp90 reduces VEGF-stimulated nitric oxide release and migration in endothelial cells. Arterioscler Thromb Vasc Biol (2007) 1.80
Phosphorylation of threonine 497 in endothelial nitric-oxide synthase coordinates the coupling of L-arginine metabolism to efficient nitric oxide production. J Biol Chem (2003) 1.80
Identification of Golgi-localized acyl transferases that palmitoylate and regulate endothelial nitric oxide synthase. J Cell Biol (2006) 1.79
High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood (2011) 1.78
Hemodialysis arteriovenous fistula patency revisited: results of a prospective, multicenter initiative. Clin J Am Soc Nephrol (2008) 1.77
Targeted deletion of nuclear factor kappaB p50 enhances cardiac remodeling and dysfunction following myocardial infarction. Circ Res (2009) 1.76
Nogo-B receptor stabilizes Niemann-Pick type C2 protein and regulates intracellular cholesterol trafficking. Cell Metab (2009) 1.76
Meta-analysis of open versus endovascular repair for ruptured descending thoracic aortic aneurysm. J Vasc Surg (2010) 1.76
Timing of aneurysm surgery in subarachnoid hemorrhage: a systematic review of the literature. Neurosurgery (2002) 1.76
Carotid stiffness and the risk of new vascular events in patients with manifest cardiovascular disease. The SMART study. Eur Heart J (2005) 1.75
Endothelial-specific expression of caveolin-1 impairs microvascular permeability and angiogenesis. Proc Natl Acad Sci U S A (2004) 1.75
Overestimation of risk ratios by odds ratios in trials and cohort studies: alternatives to logistic regression. CMAJ (2011) 1.70
Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. Blood (2003) 1.70
Caveolae, caveolins, and cavins: complex control of cellular signalling and inflammation. Cardiovasc Res (2010) 1.69
Comparison of telephone and face-to-face assessment of the modified Rankin Scale. Cerebrovasc Dis (2009) 1.69
Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol (2008) 1.68
The phosphorylation state of eNOS modulates vascular reactivity and outcome of cerebral ischemia in vivo. J Clin Invest (2007) 1.67
Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype. Eur Heart J (2013) 1.67
Outcomes of endovascular repair of ruptured descending thoracic aortic aneurysms. Circulation (2010) 1.65
Dissecting the molecular control of endothelial NO synthase by caveolin-1 using cell-permeable peptides. Proc Natl Acad Sci U S A (2005) 1.64
Stenting versus surgery in patients with carotid stenosis after previous cervical radiation therapy: systematic review and meta-analysis. Stroke (2011) 1.64
Endothelial nitric oxide synthase activation is critical for vascular leakage during acute inflammation in vivo. Proc Natl Acad Sci U S A (2005) 1.62
Caveolin-1-deficient mice have increased tumor microvascular permeability, angiogenesis, and growth. Cancer Res (2007) 1.62
Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv (2012) 1.62
Composition of carotid atherosclerotic plaque is associated with cardiovascular outcome: a prognostic study. Circulation (2010) 1.61
Dissection of the abdominal aorta. Current evidence and implications for treatment strategies: a review and meta-analysis of 92 patients. J Endovasc Ther (2009) 1.61
Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation (2007) 1.61
Percutaneous transluminal angioplasty and stenting as first-choice treatment in patients with chronic mesenteric ischemia. J Vasc Surg (2009) 1.61